Probably not but I would not rule it out entirely. Many deals are done in the pre-clinical stage (despite Benitec's comments about the need to be clinical before doing a deal) and we should have some good pre-clinical NSCLC data before the end of the year.
Hopefully we will also have some early TT-034 safety data from the first two cohorts.
time for a reality check, page-37
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)